<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Gilead</title>
	<atom:link href="http://www.tapanray.in/tag/gilead/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Innovation: Is Big Pharma Talking Differently?</title>
		<link>http://www.tapanray.in/innovation-is-big-pharma-talking-differently/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=innovation-is-big-pharma-talking-differently</link>
		<comments>http://www.tapanray.in/innovation-is-big-pharma-talking-differently/#comments</comments>
		<pubDate>Mon, 17 Sep 2018 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[differently]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Egypt]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmasset]]></category>
		<category><![CDATA[pool]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[thinking]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9139</guid>
		<description><![CDATA[“Nearly 2 billion people have no access to basic medicines, causing a cascade of preventable misery and suffering. Good health is impossible without access to pharmaceutical products.” The World Health Organization’s (WHO) ‘Access to Medicine’ report on ‘Ten years in &#8230; <a href="http://www.tapanray.in/innovation-is-big-pharma-talking-differently/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/innovation-is-big-pharma-talking-differently/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma R&amp;D: Chasing A Rainbow To Replicate The Past</title>
		<link>http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-rd-chasing-a-rainbow-to-replicate-the-past</link>
		<comments>http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/#comments</comments>
		<pubDate>Mon, 25 Jan 2016 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[exorbitant]]></category>
		<category><![CDATA[external]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Harmoni]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Nucala]]></category>
		<category><![CDATA[past]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rainbow]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[replicate]]></category>
		<category><![CDATA[return]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Treshba]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7405</guid>
		<description><![CDATA[Would future be always a replica of the past? If the response is yes, the efforts of many global pharma players to replicate the successful Research and Development (R&#38;D) models of long gone by days, would continue to be a &#8230; <a href="http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New “National IPR Policy” of India – A Pharma Perspective</title>
		<link>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-national-ipr-policy-of-india-a-pharma-perspective</link>
		<comments>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/#comments</comments>
		<pubDate>Mon, 19 Jan 2015 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Hatch]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Justice]]></category>
		<category><![CDATA[lawmakers]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[OCR]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[Orrin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prabha]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Senator]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[Sridevan]]></category>
		<category><![CDATA[Tank]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[TPF]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6330</guid>
		<description><![CDATA[Whether under pressure or not, is hardly of any relevance now. What is relevant today is the fact that the new Indian Government, almost in a record time of just around two months, has been able to release a high &#8230; <a href="http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Aggressive New Drug Pricing Trend: What It Means To India?</title>
		<link>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-aggressive-new-drug-pricing-trend-what-it-means-to-india</link>
		<comments>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/#comments</comments>
		<pubDate>Mon, 27 Oct 2014 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[aggressive]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Express]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Harmony]]></category>
		<category><![CDATA[HCV. Sovaldi]]></category>
		<category><![CDATA[Hepatitis C]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Script]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[VL]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6134</guid>
		<description><![CDATA[A new class and an aggressive drug-pricing trend is now evolving in the global pharmaceutical industry, exerting huge financial pressure on the patients and payers, including governments, especially, in the developed nations of the world. Another aspect of this issue &#8230; <a href="http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gilead: Caught Between A Rock And A Hard Place In India</title>
		<link>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=gilead-caught-between-a-rock-and-a-hard-place-in-india</link>
		<comments>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/#comments</comments>
		<pubDate>Mon, 22 Sep 2014 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alliance]]></category>
		<category><![CDATA[Between. Rock]]></category>
		<category><![CDATA[Cadila Healthcare]]></category>
		<category><![CDATA[Caught]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[Hepatitis C]]></category>
		<category><![CDATA[Hetero labs and Sequent Scientific]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[IPO. Indian]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[monopolies]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Place]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Strides Arcolab]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tenofovir]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6001</guid>
		<description><![CDATA[I had mentioned in my blog post of August 4, 2014, titled “Hepatitis C: A Silent, Deadly Disease: Treatment beyond reach of Most Indians” that in line with Gilead’s past approach to its HIV medicines, the company would offer to &#8230; <a href="http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patented Drug Pricing: Relevance To R&amp;D Investments</title>
		<link>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patented-drug-pricing-relevance-to-rd-investments</link>
		<comments>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/#comments</comments>
		<pubDate>Mon, 18 Aug 2014 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[AMP]]></category>
		<category><![CDATA[brain]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relevance R&D]]></category>
		<category><![CDATA[smarter]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5766</guid>
		<description><![CDATA[The costs of most of the new life saving drugs, used in the treatment of dreaded diseases such as cancer, have now started going north at a brisk pace, more than ever before. From the global pharma industry perspective, the &#8230; <a href="http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hepatitis C: A Silent, Deadly Disease: Treatment Beyond Reach of Most Indians</title>
		<link>http://www.tapanray.in/hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians</link>
		<comments>http://www.tapanray.in/hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians/#comments</comments>
		<pubDate>Mon, 04 Aug 2014 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[B]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[cirrhosis]]></category>
		<category><![CDATA[D]]></category>
		<category><![CDATA[E]]></category>
		<category><![CDATA[Egypt]]></category>
		<category><![CDATA[executive]]></category>
		<category><![CDATA[fibrosis]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[HCV]]></category>
		<category><![CDATA[hepatitis]]></category>
		<category><![CDATA[hepatocellular carcinoma]]></category>
		<category><![CDATA[HHS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infected]]></category>
		<category><![CDATA[inhibitor]]></category>
		<category><![CDATA[interferon]]></category>
		<category><![CDATA[IOM]]></category>
		<category><![CDATA[John]]></category>
		<category><![CDATA[liver]]></category>
		<category><![CDATA[Martin]]></category>
		<category><![CDATA[Metropolis]]></category>
		<category><![CDATA[NCDC]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pegylated]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[protease]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ribavitin]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[virus]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5697</guid>
		<description><![CDATA[Every year, July 28 is remembered as the ‘World Hepatitis Day’. In India, this year too, the day had gone by virtually uneventful, for various reasons. This happened despite increasing trend of the disease in the country. Though, there are &#8230; <a href="http://www.tapanray.in/hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leading Through The Challenge Of Change: Is Pharma Leadership Too Archaic?</title>
		<link>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic</link>
		<comments>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/#comments</comments>
		<pubDate>Mon, 16 Jun 2014 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[archaic]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Michael]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[Motors]]></category>
		<category><![CDATA[Ostrich]]></category>
		<category><![CDATA[owner]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[promoter]]></category>
		<category><![CDATA[prontosil]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Rsy]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Soman.]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tesla]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5512</guid>
		<description><![CDATA[A recent major global survey titled “Testing The Health Of The Pharmaceutical Industry” has revealed that a sizable majority of executives polled, though believe the sector is in good shape, are concerned of its reputation. Interestingly, 73 percent of respondents believe &#8230; <a href="http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Global New Product Launches: Recent Success Trend Unflattering?</title>
		<link>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=global-new-product-launches-recent-success-trend-unflattering</link>
		<comments>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/#comments</comments>
		<pubDate>Mon, 24 Mar 2014 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[10]]></category>
		<category><![CDATA[2006]]></category>
		<category><![CDATA[2007]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[FirstWord]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Januvia]]></category>
		<category><![CDATA[launches]]></category>
		<category><![CDATA[McKinsey]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[unflattering]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5132</guid>
		<description><![CDATA[New products are the lifeblood for any company, including the pharmaceutical players. Business performance and sustainable growth of the pharmaceutical industry, as a whole depend on quality of R&#38;D output in terms of &#8216;New Molecules&#8217;, followed by successful development and &#8230; <a href="http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The ‘TINA Factor’: A Hotspot for Patented Drugs</title>
		<link>http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-tina-factor-a-hotspot-for-patented-drugs</link>
		<comments>http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/#comments</comments>
		<pubDate>Mon, 16 Dec 2013 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alternative]]></category>
		<category><![CDATA[Andre]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[foist]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hepatitis]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Marijn]]></category>
		<category><![CDATA[MSF]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TINA]]></category>
		<category><![CDATA[TPP]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[virus]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4555</guid>
		<description><![CDATA[An article published in a global business magazine on December 5, 2013 mentioned that Marijn Dekkers, the CEO of Bayer AG reportedly has said at the Financial Times Global Pharmaceutical &#38; Biotech Conference held this month that: “Bayer didn’t develop its cancer drug, Nexavar (sorafenib) for &#8230; <a href="http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
